OriGene Technologies, Inc.
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right

Search Results

Your search returned 11 results.
Search:

SKU Category Vector Description Price Delivery
SC314465 Human cDNA pCMV6-Entry SRPK2 (untagged)-Human SRSF protein kinase 2 (SRPK2), transcript variant 1 NM_182692.1 $1300 2-3 weeks
RC215275 Human ORF PS100001 SRPK2 (Myc-DDK-tagged)-Human SRSF protein kinase 2 (SRPK2), transcript variant 1 $1040 Immediate
RC215275L1 Human ORF PS100064 Lenti ORF clone of Human SRSF protein kinase 2 (SRPK2), transcript variant 1 , Myc-DDK-tagged $1210 3-4 weeks
RC215275L1V Human ORF PS100064 Lenti ORF particles, SRPK2 (Myc-DDK tagged) - Human SRSF protein kinase 2 (SRPK2), transcript variant 1 , 200ul, >10^7 TU/mL $1610 6-7 weeks
RC215275L2 Human ORF PS100071 Lenti ORF clone of Human SRSF protein kinase 2 (SRPK2), transcript variant 1, mGFP tagged $1330 3-4 weeks
RC215275L2V Human ORF PS100071 Lenti ORF particles, SRPK2 (mGFP-tagged) - Human SRSF protein kinase 2 (SRPK2), transcript variant 1, 200ul, >10^7 TU/mL $1770 6-7 weeks
RG215275 Human ORF PS100010 SRPK2 (GFP-tagged) - Human SRSF protein kinase 2 (SRPK2), transcript variant 1 $1140 2-3 weeks
HP231555 Human Primer qSTAR qPCR primer pairs against Homo sapiens gene SRPK2 NM_182692 $95 3 - 5 Days
LY405411 Lysate LC405411 Transient overexpression lysate of SFRS protein kinase 2 (SRPK2), transcript variant 1 $480 5 days
LY430602 Lysate LC430602 Transient overexpression lysate of SFRS protein kinase 2 (SRPK2), transcript variant 1 $480 5 days
/ UTR pMirTarget 3`UTR clone of SFRS protein kinase 2 (SRPK2) transcript variant 1 for miRNA target validation NM_182692.1 $510 3-4 weeks
Inc 5000 Healthcare Company
All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title